AstraZeneca PLC (AZN)
| Market Cap | 202.85B |
| Revenue (ttm) | 51.21B |
| Net Income (ttm) | 6.50B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.15 |
| PE Ratio | 31.23 |
| Forward PE | 14.22 |
| Dividend | $1.48 (2.28%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 8,303,031 |
| Open | 65.45 |
| Previous Close | 65.29 |
| Day's Range | 64.97 - 65.98 |
| 52-Week Range | 60.47 - 87.68 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 88.80 (+36.53%) |
| Earnings Date | Nov 12, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $88.8, which is an increase of 36.53% from the latest price.
News
Bullish Opportunities in AZN
Tony Zhang with @OptionsPlay says AstraZeneca (AZN) has more going for it than its stock chart may show. Following the company's latest earnings, he points to strength in key metrics as a sign for bul...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management p...
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Arad...
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with th...
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesd...
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the ...
AstraZeneca's 9M and Q3 2024 results
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance...
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after ...
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in the ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZene...
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big picture looks positive. The company's numbers were strong in H1 2024 and its earn...
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society o...
China Has Detained a Senior AstraZeneca Executive
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.
AstraZeneca: China's investigation into exec separate from medical insurance probe
AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top executive, Leon Wang, is separate from a large health insurance fraud case al...
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report from ...
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill.
AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fr...
AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses
An investigation involving the drugmaker's China president is the latest industry crackdown to trigger uncertainty about Beijing's intentions.
AstraZeneca says its China operations president under investigation
AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating with Chinese authorities.